Business Description
Palisade Bio is a US-based drug development company working on a new treatment for inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Its main drug candidate, PALI-2108, is taken by mouth and is designed to deliver medicine precisely to the affected areas of the intestine, reducing the risk of side effects elsewhere in the body. The company holds several partnerships and licensing arrangements to support the development and eventual distribution of its products. Founded in 2001 and based in Denver, Colorado, Palisade Bio is currently running early-stage clinical trials to test the safety and effectiveness of its approach.
